Rob Fox

Vice President of Corporate Development

9 past transactions

CSM Parent, Inc.

Acquisition in 2018
CSM Parent, Inc. provides packaging, labelling, warehousing, and distribution services.

iQone Healthcare Holding

Acquisition in 2018
iQone Healthcare Holding operates as a speciality pharmaceutical company operating in therapeutic areas of oncology/hematology, immunology and bones and tissues.

Clinical Supplies Management

Acquisition in 2018
CSM solves complex clinical trial supply problems for biotech and pharmaceutical companies such as limited drug supply, time constraints and mid-study changes. They offer a unique blend of traditional and innovative services that can significantly shorten timelines, reduce costs and improve outcomes for clinical studies.
International Medical Management Corp. provide medical supply consulting services to the Japanese health care community.

Quantum Pharma

Acquisition in 2017
Quantum Pharma is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler and hospital markets. Quantum Pharma operates through two divisions incorporating seven business units across six sites in the UK and Europe, offering a portfolio of innovative and synergistic products and services.

Totect

Acquisition in 2016
Totect® is the first and only approved treatment by the United States Food and Drug Administration for anthracycline extravasation.

Link Healthcare

Acquisition in 2015
Link Healthcare, a specialist pharma company focused on markets in Asia, Africa and Australasia

IDIS

Acquisition in 2015
Around the world, patients with unmet medical needs are frequently driven to seek access to medicines outside the clinical trial and commercial setting. Idis is the leading expert in developing, implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients. Idis has over 27 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from virtually every therapeutic category, impacting the lives of hundreds of thousands of patients. Around the world, a variety of terms are used to describe these programs including “expanded access”, “named patient”, “ATU”, “compassionate use”, and “early access”.

Clinigen CTS Ltd

Acquisition in 2010
Clinigen CTS Limited supplies drugs and ancillaries for global trials.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.